item management s discussion and analysis of financial condition and results of operations overview the company is engaged in research and development and chemical library production for collaborations and for its own use 
the company s research and development has focused on efficient  cost effective  high throughput systems for synthesizing and screening large libraries of chemicals for new drug discovery and optimization 
during  the company signed new agreements with bayer  daiichi and nv organon  to bring the total number of pharmaceutical company collaborators to six 
in addition  the company signed contracts to extend the schering plough and berlex agreements 
the company recognized revenue from all six collaborations during the company received its initial revenues in the year ended december  pursuant to drug discovery collaboration and chemical library licensing agreements with schering plough and berlex 
the company was in the development stage through december and has incurred cumulative net losses of approximately million since inception through december  results of operations the company expects that its revenue sources for at least the next several years will be limited to future collaboration payments from schering plough  berlex  sandoz  bayer  daiichi and nv organon and from other customers under arrangements that may be entered into in the future 
the timing and amounts of such revenues  if any  will likely fluctuate 
historical results should not be viewed as indicative of future operating results 
the company will be required to conduct significant research  development and production activities during the next several years to fulfill its obligations under the schering plough  berlex  sandoz  bayer  daiichi  and nv organon collaborative agreements and to develop other collaborations and technologies 
the company does not anticipate having net income in the next several years 
years ended december  and revenues increased to million in  compared to million in the increase of million primarily reflects expanded efforts in the company s collaborations with schering plough  berlex  sandoz  bayer  daiichi and nv organon 
the revenues were attributable entirely to the schering plough and berlex collaborations 
the company s sources of revenues for the next several years will be interest income  payments under its current collaborations and payments from other customers  to the extent that the company enters into any additional arrangements 
the company incurred research and development expenses of million and million in the years ended december  and  respectively 
these increased amounts primarily reflect increased salaries and personnel expenses as the company continued to hire additional research and development personnel  equipment depreciation and facilities expenses and laboratory supplies purchased in connection with the expansion of the company s chemical library production and screening efforts for collaborations and for its own use 
research and development expenses are expected to continue to increase as the company further expands its activities and incurs  among other things  expenses related to additional staff increases  increased rent for expanded facilities  and increased equipment and reagent purchases 
general and administrative expenses were million and million in the years ended december  and  respectively 
the increase is primarily attributable to increased payroll and personnel expenses as the company hired additional management and administrative personnel and incurred additional legal  insurance and other professional fees in connection with the overall scale up of the company s operations 
general and administrative expenses are also expected to increase as the company s research staff continues to expand 
years ended december  and revenue from the schering plough and berlex collaborations totaled approximately million for the year ended december  the company did not have any revenue during the company incurred research and development expenses of approximately million and million in the years ended december  and  respectively 
these amounts were spent primarily for salaries  equipment depreciation and facilities expense  and laboratory supplies 
the increase in from reflects the increase in the company s research and development activities attributable to the new collaborative agreements with schering plough and berlex 
general and administrative expenses were approximately million and million in the years ended december  and  respectively 
these expenses include salaries  legal and accounting fees and other expenses 
liquidity and capital resources as of december   the company had working capital of million 
the company has funded its activities through december  primarily through the sale of equity securities and funding under collaborative arrangements 
from inception through december   the company received million in net proceeds from equity financing and received million in research and development and license fees under collaborative agreements 
the company s funds are currently invested in us treasury and government agency obligations  investment grade commercial paper and other short term money market instruments 
the company may also invest such proceeds in investment grade  interest bearing securities having a maximum maturity of two years 
as of december   the company s cash and cash equivalents totaled million 
in addition  the company had marketable securities of million 
see note of notes to financial statements 
in connection with the company s agreement with the trustees of columbia university and cold spring harbor laboratory  the company is required to pay annual license fees 
as of december   the company had met its obligation under the agreement to expend million and million in development and commercialization of the licensed technology for the one year periods ending july and july  respectively 
the company is also required to pay to columbia university certain royalties 
in addition  as of december   the company had outstanding commitments for construction and equipment purchases totaling million 
the company anticipates that its capital requirements will increase over the next two years as the company expands its research and development activities 
in connection with such expansion  the company expects to incur substantial expenditures for hiring additional management  scientific and administrative personnel and for planned expansion of its facilities and replacement of laboratories currently subleased  including acquisition of additional equipment 
as of december   the company had federal net operating loss carryforwards of million 
these carryforwards will expire beginning in the year utilization of the net operating loss carryforwards will be subject to limitation under section of the internal revenue service code 
see note of notes to financial statements 
the company anticipates that its existing capital resources will be adequate to fund the company s operations at least through there can be no assurance that changes will not occur that would consume available capital resources before such time 
the company s capital requirements depend on numerous factors  including the ability of the company to enter into additional collaborative arrangements  competing technological and market developments  changes in the company s existing collaborative relationships  the cost of filing  prosecuting  defending and enforcing patent claims and other intellectual property rights  the purchase of additional capital equipment  acquisitions of other business or technologies  the progress of the company s drug discovery programs and the progress of the company s customers milestone and royalty producing activities 
there can be no assurance that additional funding  if necessary  will be available on favorable terms  if at all 
the company s forecasts of the period of time through which its financial resources will be adequate to support its operations is forward looking information  and actual results could vary 
the factors described earlier in this paragraph will impact the company s future capital requirements and the adequacy of its available funds 

